News | March 13, 2025
Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
The trademark rights for these brands will be transferred to Lupin by March next year.
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Subscribe To Our Newsletter & Stay Updated
